|
Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role? |
journalArticle |
2016 |
Ou, D.; Levy, A.; Blanchard, P.; Nguyen, F.; Garberis, I.; Casiraghi, O.; Scoazec, J. Y.; Janot, F.; Temam, S.; Deutsch, E.; Tao, Y. |
|
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab |
journalArticle |
2016 |
Hua, C.; Boussemart, L.; Mateus, C.; Routier, E.; Boutros, C.; Cazenave, H.; Viollet, R.; Thomas, M.; Roy, S.; Benannoune, N.; Tomasic, G.; Soria, J. C.; Champiat, S.; Texier, M.; Lanoy, E.; Robert, C. |
|
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene |
journalArticle |
2016 |
van Kempen, L. C.; Redpath, M.; Elchebly, M.; Klein, K. O.; Papadakis, A. I.; Wilmott, J. S.; Scolyer, R. A.; Edqvist, P. H.; Ponten, F.; Schadendorf, D.; van Rijk, A. F.; Michiels, S.; Dumay, A.; Helbling-Leclerc, A.; Dessen, P.; Wouters, J.; Stass, M.; Greenwood, C. M.; Ghanem, G. E.; van den Oord, J.; Feunteun, J.; Spatz, A. |
|
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30 |
journalArticle |
2016 |
Blanchard, P.; Briganti, A.; Bossi, A. |
|
Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma |
journalArticle |
2016 |
Gorphe, P.; Matias, M.; Even, C.; Ferte, C.; Bidault, F.; Garcia, G.; Temam, S.; Nguyen, F.; Blanchard, P.; Tao, Y.; Janot, F. |
|
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30 |
journalArticle |
2016 |
Blanchard, P.; Briganti, A.; Bossi, A. |
|
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis |
journalArticle |
2017 |
Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y. |
|
Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy |
journalArticle |
2017 |
Annede, P.; Seisen, T.; Klotz, C.; Mazeron, R.; Maroun, P.; Petit, C.; Deutsch, E.; Bossi, A.; Haie-Meder, C.; Chargari, C.; Blanchard, P. |
|
Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow |
journalArticle |
2017 |
Blanchard, P.; Menard, C.; Frank, S. J. |
|
Enjeux méthodologiques de la médecine de précision en oncologie |
journalArticle |
2017 |
Asselain, B.; Paoletti, X. |
|
Letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?" |
journalArticle |
2017 |
Hill, C.; Asselain, B. |
|
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study |
journalArticle |
2017 |
Bredart, A.; Bodson, S.; Le Tourneau, C.; Flahault, C.; Bonnetain, F.; Beaudeau, A.; Coquan, E.; Dolbeault, S.; Paoletti, X. |
|
Statistical approaches for evaluating body composition markers in clinical cancer research |
journalArticle |
2017 |
Bayar, M. A.; Antoun, S.; Lanoy, E. |
|
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification |
journalArticle |
2017 |
Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J. |
|
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials |
journalArticle |
2017 |
Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F. |
|
[Proton therapy for head and neck cancers] |
journalArticle |
2017 |
Blanchard, P.; Frank, S. J. |
|
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study |
journalArticle |
2017 |
Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L. |
|
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis |
journalArticle |
2017 |
Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y. |
|
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice |
journalArticle |
2017 |
Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M. |
|
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification |
journalArticle |
2017 |
Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J. |
|
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors |
journalArticle |
2017 |
Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C. |
|
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
|
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial |
journalArticle |
2017 |
Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V. |
|
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study |
journalArticle |
2017 |
Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S. |
|
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? |
journalArticle |
2017 |
Blanchard, P.; Bossi, A.; Fizazi, K. |
|
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials |
journalArticle |
2017 |
Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F. |
|
The frequency of cancer in France: Most recent data and trends |
journalArticle |
2017 |
Ribassin-Majed, L.; Le-Teuff, G.; Hill, C. |
|
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
|
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial |
journalArticle |
2017 |
Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C. |
|
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients |
journalArticle |
2017 |
Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C. |
|
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study |
journalArticle |
2017 |
Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A. |
|
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? |
journalArticle |
2017 |
Blanchard, P.; Bossi, A.; Fizazi, K. |
|
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? |
journalArticle |
2017 |
Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S. |
|
In Regard to Arthurs et al |
journalArticle |
2017 |
Blanchard, P.; Garden, A. S. |
|
Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma |
journalArticle |
2017 |
Conversano, A.; Mazouni, C.; Thomin, A.; Gaudin, A.; Fournier, M.; Rimareix, F.; Bonastre, J. |
|
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study |
journalArticle |
2017 |
Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L. |
|
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial |
journalArticle |
2017 |
Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C. |
|
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study |
journalArticle |
2017 |
Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A. |
|
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium |
journalArticle |
2017 |
Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X. |
|
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? |
journalArticle |
2017 |
Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S. |